HLNE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hamilton Lane Inc (HLNE) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available. The company's strong financial performance, stable revenue model, limited exposure to private credit risks, and recent analyst upgrades with significant upside potential make it an attractive investment opportunity. Despite short-term technical indicators suggesting potential minor declines, the long-term growth prospects outweigh these concerns.
The MACD is positively expanding, suggesting bullish momentum. RSI is neutral at 67.601, indicating no overbought or oversold conditions. Moving averages are converging, signaling potential price consolidation. Key resistance levels are at 107.129 and 111.795, while support levels are at 92.025 and 87.359. Short-term stock trend analysis shows a 60% chance of minor declines (-0.2% in a day, -4.2% in a week, -7.88% in a month), but these are not significant for a long-term investor.
JPMorgan upgraded HLNE to Overweight with a $166 price target, indicating a 58% upside.
Analysts believe fears around AI and private credit risks are exaggerated, particularly for Hamilton Lane.
The company's revenue model is stable, with management fees driving growth and wealth inflows remaining strong.
Financials show strong YoY growth in revenue (+27.39%), net income (+10.19%), and EPS (+3.79%) in Q3 2026.
Concerns about private credit and AI-driven disruption have caused a 22% decline in stock price.
Broader market volatility and widening credit spreads may impact alternative asset managers.
Short-term technical indicators suggest potential minor declines in the stock price.
In Q3 2026, Hamilton Lane's revenue increased by 27.39% YoY to $218.27 million, net income rose by 10.19% YoY to $58.37 million, and EPS grew by 3.79% YoY to 1.37. These figures indicate strong financial growth and stability.
Recent analyst ratings are positive, with JPMorgan upgrading the stock to Overweight and maintaining a $166 price target. Oppenheimer and Keefe Bruyette also maintain Outperform ratings, with adjusted price targets of $171 and $120, respectively. Analysts view the recent selloff as an overreaction and suggest using the weakness to add to positions.
